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ABSTRACT
SMYD3 is a methylase previously linked to
cancer cell invasion and migration. Here we
show that SMYD3 favors TGF-induced epithelial–
mesenchymal transition (EMT) in mammary epithelial
cells, promoting mesenchymal and EMT transcrip-
tion factors expression. SMYD3 directly interacts
with SMAD3 but it is unnecessary for SMAD2/3 phos-
phorylation and nuclear translocation. Conversely,
SMYD3 is indispensable for SMAD3 direct associa-
tion to EMT genes regulatory regions. Accordingly,
SMYD3 knockdown or its pharmacological blockade
with the BCI121 inhibitor dramatically reduce TGF-
induced SMAD3 association to the chromatin. Re-
markably, BCI121 treatment attenuates mesenchymal
genes transcription in the mesenchymal-like MDA-
MB-231 cell line and reduces their invasive ability in
vivo, in a zebrafish xenograft model. In addition, clin-
ical datasets analysis revealed that higher SMYD3
levels are linked to a less favorable prognosis in
claudin-low breast cancers and to a reduced metas-
tasis free survival in breast cancer patients. Overall,
our data point at SMYD3 as a pivotal SMAD3 cofactor
that promotes TGF-dependent mesenchymal gene
expression and cell migration in breast cancer, and
support SMYD3 as a promising pharmacological tar-
get for anti-cancer therapy.
INTRODUCTION
A crucial event occurring in the metastatic process is the
epithelial–mesenchymal transition (EMT), which endows
tumor cells with the ability to trans-differentiate from ep-
ithelial to mesenchymal-like cells and to acquire the capa-
bility to leave the primary tumor mass and disseminate at
distant sites (1,2). EMT has been extensively linked to both
metastatic progression of cancer (1,3) and acquisition of
stem-cell properties (4,5), strengthening the hypothesis that
reprogramming from epithelial to mesenchymal phenotype
leads to acquiredmigration and self-renewal abilities, which
foster the formation of secondary tumors at distant sites.
Specific extracellular signals activate the EMT and pro-
mote epithelial cells reprogramming towards a mesenchy-
mal phenotype (6). During this process, epithelial features
such as cell-cell adhesion, polarity and lack of motility are
lost, and cells acquire mesenchymal characteristics, includ-
ing motility and ability to invade. In breast cancer pro-
gression, EMT is triggered and maintained by various ex-
tracellular signals promoting either autocrine or paracrine
stimuli. Among these signals, the transforming growth beta
(TGF) signaling pathway plays a crucial role (1,3,7). Evo-
lution to invasive and metastatic forms of breast cancer
correlates with the activation of EMT (6,8,9) and with in-
creased levels of TGF-1 in plasma of breast cancer patients
and at the invasive front in human breast cancer tissue sec-
tions (10,11).
TGF signaling pathway activation results in SMAD2
and SMAD3 phosphorylation, their association with
SMAD4, and translocation to the nucleus, where
SMAD2/3 promote transcriptional activation of EMT-
inducing transcription factors (EMT-TFs): Snail1, Slug,
ZEB1/2, Twist1/2 and Sox4 (12,13). SMAD2/3/4
transcription factors orchestrate the epithelial cell repro-
gramming in concert with epigenetic factors that regulate
epigenome plasticity and coordinate the expression of
molecular signatures associated with the EMT program
(14,15). Different DNA-binding partners confer SMADs
target gene selectivity and influence the recruitment of
transcriptional coactivators or co-repressors. SMADs
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can bind to acetyltransferases as p300 and P/CAF, but
also histone deacetylases and chromatin repressors, which
contribute to target genes regulation (8,16).
Expression profiles analysis of human breast cancers al-
lowed the identification of at least five different molecular
subtypes (luminal A, luminal B, Her2+, basal and claudin-
low) (17,18). Among these subtypes, claudin-low tumors ex-
press characteristic mesenchymal genes, and the EMT sig-
nature is particularly enriched in this set of tumors, which
associate with poorer prognosis (19,20).
The methylase SMYD3 was reported to promote cancer
cells proliferation and invasion, and to be over-expressed
in several cancers, e.g. colorectal, pancreatic, liver and
breast cancers, and was also identified in gene signatures
of metastatic pancreatic cancer cells (21–25). SMYD3 has
been reported to regulate the metalloprotease MMP9 and
cancer invasion (26–29). Recently, Sarris et al. (23) de-
scribed that SMYD3 is recruited at chromatin regulatory
regions of proliferation and EMT genes, in mouse models
of liver and colon cancers and the authors depict SMYD3
as a transcriptional ‘potentiator’ for proliferation and EMT
genes, during cancer progression (23).
Nevertheless, although SMYD3 oncogenic function is
well established, the molecular mechanism through which it
promotes tumor cells migration and invasion has not been
fully described yet. To elucidate the underlying dynamics of
SMYD3-mediated regulation of EMT, we employed breast
cancer cells as a model system and investigated SMYD3
link with the TGF/SMADs signaling pathway. Here, we
report that SMYD3 is indispensable for SMAD3 mediated
regulation of target genes, in TGF treated breast cancer
cells. SMYD3 blockade with the BCI121 inhibitor reduced
cell motility, both in cell cultures and in an in vivo model
of zebrafish xenograft. Our study provides novel insight in
TGF-induced transcriptional activation and it supports
SMYD3 as a promising therapeutic target for cells that un-
dergo EMT.
MATERIALS AND METHODS
Cell cultures and reagents
NMuMG, MCF10A and MDAMB231 cell lines were pur-
chased from the American Type Culture Collection, grown
in DMEM supplemented with 10% FBS, 100 U/ml peni-
cillin and 100 mg/ml streptomycin. MCF10A cell line was
grown inDMEMF-12 supplementedwith 5%HS, 20 ng/ml
EGF, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin,
10g/ml insulin, 100U/ml penicillin and 100mg/ml strep-
tomycin. Cells were grown in a humidified incubator with
5% CO2 at 37◦C. Cells were starved in serum free growth
medium for 12 h and then they were fed with fresh medium
containing FBS and 5 ng/ml TGF.
TGF was reconstituted in 10 mM citric acid (pH 3.0)
to a final concentration of 0.1 mg/ml, then further diluted
in PBS containing 0.1% BSA to a final concentration of
0.01mg/ml and stored at –20◦C. BCI121 (Innovamol, Italy)
was dissolved in dimethyl sulfoxide (DMSO) and stored at
–20◦C. Unless differently described, BCI121 was used at a
final concentration of 10 M.
All cell lines were periodically tested for mycoplasma
with MycoAlert Mycoplasma detection kit (Euroclone,
Italy). All cell lines were fed every 48/72 h, for a maximum
number of 30 passages. mSMYD3 expression plasmid was
purchased from Origene (PS100001).
Cell proliferation and wound healing assays
Cells growthwas determinedwith a Bu¨rker chamber, count-
ing cells after 48 or 72 h of BCI121 or DMSO exposure.
Wound healing assays was performed using Dish
Culture–Inserts (Ibidi). 50 000 cells per well were plated and
dish were incubated at 37◦C and 5% CO2. After 24 h, the
Culture-Insert was removed and medium was changed. Pic-
tures were taken at time 0 and 16 h, to evaluate migra-
tion ability. The ‘wounded’ area wasmanually selected (blue
lines) and quantified with ImageJ.
RNA tsolation and real time PCR (qRT-PCR)
Total RNA was extracted using TRI reagent (Sigma) ac-
cording to the manufacturer’s instruction. cDNA was syn-
thesized from RNA (1g) using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystem). qRT-PCR
was performed in triplicate using SYBR Green PCR Mas-
ter Mix (Bio-Rad) or 2X Xtra Master Mix (GeneSpin)
on a CFX Connect Real-Time PCR Detection System
(Bio-Rad). The qRT-PCR reactions were normalized using
GAPDH as housekeeping gene and relative quantification
was done using the ddCT method. List of primers used in
this study can be found in supplementary methods.
RNA interference and retroviral infections
siRNAs targeting human SMYD3 (5′-
GAUUGAAGAUUUGAUUCUA-3′) were synthetized
by Eurofins Genomics, and SMAD2/3 siRNAs were
purchased from Santa Cruz Biotechnology (sc-37238). siR-
NAs were transfected (150nM) with Lipofectamine 2000
according to the manufacturer’s instructions. Scrambled
siRNA (5′-GCGUUGCUCGGAUCAGAAA-3′) was used
as negative control. shRNAs used for retroviral/lentiviral
infections and siRNA transfection in NMuMG cells
were previously described (30). Retroviral and lentiviral
infections were performed as in (31). Retrovirus carrying
full-length hSMYD3 or SMYD3 mutants were previously
described (30).
Cell extracts and immunoblot analysis
Cells were collected and homogenized in RIPA lysis buffer
(50 mMTris–HCl pH 7.4, 0,5% sodium deoxycholate, 0,1%
SDS, 250 mMNaCl and 1%NP40) supplemented with pro-
tease and phosphatase inhibitors (Sigma). Homogenates
were solubilised in Laemmli Sample buffer and 30 g pro-
teins were separated on 8%, 10% or 12% SDS-PAGE, and
transferred to nitrocellulose membranes using Trans-Blot
TurboTransfer System (BioRad).Membranes were blocked
with 5% nonfat dry milk in PBS/0.1% Tween and incu-
bated with primary antibody, overnight. Employed anti-
bodies were: E-caderin (Cell Signaling, 24E10), Occludin
(Santa Cruz, sc-5562), Fibronectin (Santa Cruz, sc-9068),
SMYD3 (GeneTex, GTX121945), SMYD3 (Cell Signal-
ing, D2Q4V), Snail1 (Cell Signaling, C15D3), Actin (Santa
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Cruz, sc-8432), p-SMAD2/3 (Santa Cruz, sc-11763), Vi-
mentin (Santa Cruz, sc-6260), SMAD4 (Santa Cruz, sc-
7966), histone H3 (Santa Cruz, sc-10809), Flag (Sigma,
F3165), HA (Santa Cruz, sc-805), Snail2 (Santa Cruz,
sc-166476), Lamin A/C (Cell Signaling, 4C11), c-myc
(Santa Cruz, sc-789), AKT1/2/3 (Santa Cruz, sc-8312), p-
AKT1/2/3 (Santa Cruz, sc-7985-R), ERK (Santa Cruz,
sc-94), p-ERK (Santa Cruz, sc-sc-7383), GAPDH (Santa
Cruz, sc-32233). Nuclear and cytoplasmic extracts were
performed with Nuclear Extract Kit (Active Motif) or ac-
cording to the procedure described in (32). Images derived
fromWestern blot were quantified using ImageJ (NIH,MD,
USA) software.
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation was performed as previ-
ously described (33). MCF10A and NMuMG cells were
treated with 5 ng/ml TFG for 6 hrs before formaldehyde
crosslinking. 2g of SMYD3 (NovusBio,NBP1-79393) and
SMAD2/3 (Cell Signaling, D7G7) antibodies were used in
MCF10A cells, SMYD3 (GeneTex, GTX121945), SMAD3
(Abcam, ab28379) RNAPolII (GeneTex), H3K4me3 (Milli-
pore, 05-745),H3K27me3 (ActiveMotif, 39536),H3K9me3
(Active Motif, 39161), H3K9Ac (Millipore, 06-942). List of
primers used in this study can be found in supplementary
methods.
Recombinant proteins
GST-SMYD3 was expressed in Escherichia coli TUNER
cells, previously transfected with the Chaperone pKJE7
plasmid (Takara), by induction with 0.1 mM IPTG O/N at
4◦C. Recombinant GST-SMYD3 was purified using Pierce
Glutathione Superflow Agarose resin (Thermo Scientific)
and eluted with 125 mM Tris–HCl, 150 mM NaCl, 10 mM
reduced glutathione, 0.2% Triton X100, pH 8.0. GST tag
was removed with PreScission Protease (GE Healthcare),
according to the manufacturer’s instructions.
Immunoprecipitation
Whole cell extracts were obtained from HEK293T trans-
fected cells or NMuMG cells collected and homogenized in
IP lysis buffer (50mMTris–HCl pH8, 150mMNaCl, 5mM
MgCl2, 2 mM EDTA, 10% glycerol, 0.1% NP40) supple-
mented with protease and phosphatase inhibitors (Sigma,
Italy). Cytoplasmic/nuclear fractionationwas performed as
in (32) and 500 g of both extracts was employed for im-
munoprecipitation.
Protein contents of all the samples were determined
by the Bradford’s method. 500 g of whole extract were
incubated with Myc (Millipore, 05-419), SMYD3 (Santa
Cruz, sc-49519X), normal IgG (Santa Cruz, sc-2027, sc-
2028) at 4◦C for 2 h and Protein G Agarose beads (Pierce,
Italy) were added for 45 additional minutes. IP for Flag
were performed with Flag-M2 affinity gel (Sigma, A2220).
For IP with recombinant proteins, 200ng of GST-SMAD3
(Sigma, Italy) and SMYD3 were incubated with 2g of
anti-SMYD3 antibody (Santa Cruz, sc-49519X) or with
goat IgG (Santa Cruz, sc-20208) in IP Buffer (50 mM Tris–
HCl, 1 mM EDTA, 150 mM NaCl, 5 mM MgCl2, 10%
glycerol, 0.1% NP40, pH 8.0) and incubated at 4◦C for 2
h and Protein G Agarose beads (Pierce, Italy) were added
for 45 additional minutes. Immuno-complexes were washed
3 times, resolved by SDS-PAGE and analyzed by Western
blot with SMAD2/3 (Cell Signaling, D7G7), HA (Santa
Cruz, sc-805), Flag (Santa Cruz, sc-807), SMYD3 (Gene-
Tex, GTX121945).
Immunofluorescence
Cells seeded on coverslips were washed with PBS, fixed
in methanol and blocked with 3% BSA in 1XPBS 0.02%
Triton for 1 h at room temperature. Samples were then
probed overnight with Paxillin (Santa Cruz, 5574), ZO1
(Santa Cruz 10804), N-cadherin (Santa Cruz, 7939), Phal-
loidin (Santa Cruz, sc-363795), p-SMAD3 (Cell Signaling,
C25A9). After three 5 min washes with PBS, cells were in-
cubated at room temperature with rabbit or mouse Alexa
Fluor secondary antibodies for 1 h. Cells were then washed
three times with PBS/Triton for 5 min, coverslips were
mounted on slides with Fluoroshield with DAPI (Sigma).
The samples were examined with a fluorescence microscope
(Zeiss). Pictures of staining were obtained using an Axio-
Cam (Carl Zeiss Vision).
Zebrafish care and tumor xenograft
Tg(fli1a:EGFP)y1 transgenic embryos, collected by natural
spawning, were staged and raised at 28◦C in fish water (In-
stant Ocean, 0.1% methylene blue), according to National
(Italian D.lgs 26/2014) and European laws (2010/63/EU
and 86/609/EEC). Dechorionated embryos at 48 h postfer-
tilization hpf were anesthetized with 0.04 mg/ml of tricaine
(Sigma-Aldrich). Tumor cells, labeled with a red fluorescent
dye for cell viability (CellTracker™CM-DiI, Invitrogen) and
resuspended in PBS, were implanted in the sub-peridermal
space, close to the sub-intestinal vessels (SIV) plexus, of 48
hpf zebrafish embryos (100 cells for each embryo). After
cell implantation, embryos showing cells into the yolk sac
and/or in the vasculature embryos were excluded from fur-
ther analyses. Correctly grafted embryos were split in two
experimental groups that were treated with 50 M BCI121
and the vehicle alone (DMSO). BCI121 and DMSO were
diluted directly into the fish water. Treated and control em-
bryos were incubated at 32◦C. At 48 h post injection (hpi),
the presence of circulating grafted cells into the trunk/tail
region was evaluated through a fluorescence stereomicro-
scope (Leica DM6000B equipped with LAS Leica imaging
software). The spread of injected tumor cells throughout the
embryo was quantified in both 50 M BCI121-treated and
control embryos by the ‘Analyze Particle’ plugin of Fiji soft-
ware. Data from two independent experiments were pooled.
Statistical significance was calculated with unpaired Stu-
dent’s t-test. *P < 0.05.
Clinical datasets analysis
The website FireBrowse (http://firebrowse.org) was used to
interrogate the TGCA database for the average SMYD3 ex-
pression in breast invasive carcinomas versus normal tissue.
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The website cBioPortal (http://www.cbioportal.org) was
used for meta-analysis (34,35). The Metabric dataset con-
tains data from 2509 patients with breast cancer, and in-
cludes Illumina v3 RNA microarray and clinical data with
a follow-up period up to 350 months (36,37). Only 1866 pa-
tients were included in the present study, because they dis-
played all the parameters considered. Patients were strat-
ified based on SMYD3 z-score and quartiles were identi-
fied as SMYD3 high (q1: SMYD3 z-score≥ 0.998. n= 468)
and SMYD3 low (q3 SMYD3 z-score ≤ –0.327. n = 467).
SMYD3 expression levels were correlated with EMT genes
transcript levels by Pearson correlation analysis. Estimated
probability of overall survival and distant metastasis free
survival was calculated with the Kaplan-Meier method.
NKI295 dataset was downloaded from http://ccb.nki.nl/
data/ (38). Correlation analysis in the NKI295 set was lim-
ited to the available data for EMT-related target probes. The
subgroup of patients with BRCA1 mutations was excluded
from the analysis.
Statistical analysis
Statistical significance of the results was analyzed using
the unpaired Student’s t-tail test, one-way Anova followed
by Tukey post-test, two-way Anova followed by Bonfer-
roni post-test using GraphPad (Prism6). Survival curves
were analyzed by Log-rank (Mantel-Cox) Test. Correla-
tions were analyzed by Pearson test. *P < 0.05, **P <
0.01 and ***P < 0.001 were considered statistically signifi-
cant.
RESULTS
SMYD3 is required for efficient TGF-induced EMT
Our analysis of the Human Cancer Genome Atlas (TCGA)
database (34,35) revealed that SMYD3 transcripts are over-
expressed in a variety of cancers, and amplification fre-
quency measured by RNA transcript levels is especially ap-
parent in several breast cancers cohorts (Supplementary
Figure S1A).
In addition to its role in cancer cells proliferation,
SMYD3 was shown to regulate EMT genes (23). Since
EMT is causatively linked to distant metastases for ep-
ithelial cancers including breast cancer, we initially tested
SMYD3 role in EMT employing mouse mammary gland
epithelial (NMuMG) cells, which can be induced to un-
dergo EMT when treated with TGF. We knocked down
SMYD3 levels by Sh-interference, using a retrovirus car-
rying a short-hairpin sequence targeting SMYD3. As ex-
pected, following TGF treatment, ShScramble NMuMG
cells morphology acquired a mesenchymal phenotype (Fig-
ure 1A, upper panels), accompanied by the progres-
sive down-regulation of epithelial transcripts E-cadherin
and Claudin6 (Supplementary Figure S2A). Remarkably,
ShSMYD3 cells maintained a more epithelial morphol-
ogy (Figure 1A, lower panel) and the epithelial transcripts
E-Cadherin and Claudin6 failed to decrease (Supplemen-
tary Figure S2A). Immunoblot analysis revealed that E-
Cadherin and Occludin protein levels were maintained at
higher levels following TGF stimulation, when compared
to ShScramble cells at 96 h of TGF treatment (Figure 1B).
Moreover, ShSMYD3 silencing reduced TGF induced up-
regulation of the mesenchymal markers Fibronectin1 and
N-cadherin, when compared to ShScramble cells (Figure 1B
and Supplementary Figure S2A). Snail1, which plays a crit-
ical role in the transcriptional repression of epithelial genes
and transition to a mesenchymal phenotype during EMT
(39), failed to be upregulated both at the transcriptional
and protein level in ShSMYD3 cells (Figure 1C). More-
over, AKT and ERK phosphorylation levels, which were
shown to be affected by SMYD3 depletion in previous re-
ports (25,40,41), remained unchanged in our model system
(Supplementary Figure S2B).
F-actin and Paxillin immunostaining revealed that
SMYD3 depletion did not affect the epithelial morphol-
ogy of NMuMG cells in the absence of TGF. Follow-
ing TGF treatment, instead, expression of the epithelial
marker ZO-1was retained at the cell membrane of SMYD3-
depleted cells, and the signal for the mesenchymal marker
N-cadherin was barely detectable in ShSMYD3 cells (Fig-
ure 1D). TGF induced stress fibers and focal adhesion for-
mation, revealed by F-actin and paxillin staining respec-
tively, were almost absent in ShSMYD3 cells and revealed
reduced remodeling of cytoskeleton, when compared to
ShScramble TGF-treated cells (Figure 1D).
Similar results were obtained in immortalized benign
MCF10A human mammary epithelial cells, in which the
cuboidal cobblestone epithelial cells switch to a fibroblas-
toid morphology following TGF treatment (Supplemen-
tary Figure S2C, top panel). SMYD3 depletion by RNA
interference led to a persistency of the epithelial morphol-
ogy, upon TGF treatment (Supplementary Figure S2C,
bottom panel); this lack of morphological change was
accompanied by a delay in mesenchymal marker expres-
sion (N-cadherin, Vimentin, Fibronectin1 and MMP9) in
TGF-treated SMYD3-depleted cells (Figure 1E). In ad-
dition, when SMYD3-deficient and control cells were ex-
posed to TGF for 6 h, mRNA levels of a subset of EMT-
TFs (Snail1, Snail2, Sox4, Twist1) failed to be upregulated
in SMYD3-knockdown cells (Figure 1F). Concurrently,
mRNA and protein levels of the epithelial marker Occludin
were maintained at higher level in SMYD3-depleted cells,
when compared to control scramble interfered cells (Figure
1E). Protein levels of the mesenchymal markers Snail1, Fi-
bronectin and N-cadherin decreased in SMYD3-depleted
MCF10A cells and their expression was rescued by re-
constitution with a mouse SMYD3 protein, which pro-
moted the upregulation of mesenchymal markers and led
to a reduction of Occludin levels (Figure 1G). Likewise,
in ShSMYD3 NMuMG cells, the reconstitution with the
hSMYD3 protein (Supplementary Figure S2D) promoted
the mesenchymal transcripts expression and reduced Oc-
cludin transcript levels (Supplementary Figure S2E). Both
in NMuMG and MCF10A cells, SMYD3 transcript levels
tended to slightly increase following TGF administration
(Supplementary Figure S2F,G). Nonetheless, SMYD3 pro-
tein levels were not significantly affected by TGF treat-
ment in our NMuMG model (Figure 1B).
Since TGF treatment promotes cell migration in epithe-
lial breast cancer cells (2), we evaluated SMYD3 impact on
cell migration through a wound-healing assay. We observed
that SMYD3 knockdown reduced TGF-induced migra-
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gky1221/5245441 by U
niversità degli Studi di M
ilano user on 28 D
ecem
ber 2018
Nucleic Acids Research, 2018 5
Figure 1. SMYD3 depletion impairs TGF-induced EMT in NMuMG andMCF10A cells. (A) Brightfield images of shSMYD3 or shScramble NMuMG
cells treatedwith 10 ng/mlTGF or vehicle for 24 h. Scale bar= 10m. (B)Western blot analysis of epithelial (E-Cadherin andOccludin) andmesenchymal
(N-Cadherin and Fibronectin) genes in shSMYD3 or shScramble NMuMG cells treated with 10 ng/ml TGF for 0, 48, 72 and 96 h. GAPDH serves as
a loading control. Normalized band intensity in immunoblots is reported above signals. (C) Upper panel: Snail1 transcript levels were quantified by qRT-
PCR, after 0, 6, 12 h of TGF treatment. Data represent means±SD. Statistical analysis was performed with one-way ANOVA, followed by post-hoc
Tukey test. n ≥3, * P ≤ 0.05. Lower panel: Western blot to evaluate Snail1 protein levels at 0, 6 12, 24 h following TGF treatment. -actin was used as
loading control. Normalized band intensity in immunoblots is reported above signals. (D) immunofluorescence microscopy of mesenchymal and epithelial
markers in shSMYD3 or shScramble NMuMG cells. Left panels show untreated cells and the right panel shows cells treated with 10 ng/ml TGF for 24 h.
Epithelial (ZO-1) and mesenchymal (N-Cadherin) markers were analyzed. Paxillin was used to detect focal adhesion plaques, and phalloidin to visualize
the actin cytoskeleton. Scale bar = 20 m. (E) MCF10A cells were treated with 5 ng/ml TGF for 72 h and mRNA levels of epithelial (Occludin) and
mesenchymal genes (MMP9, Vimentin, N-Cadherin and Fibronectin) were determined by quantitative real-time PCR analysis, relative to GAPDH. Data
represent means ± SD of nFold relative to a SiScramble untreated sample. Statistical analysis was performed with unpaired Student’s t test. n≥3, * P ≤
0.05, **P≤ 0.01. (F)MCF10A cells were incubated with Scramble or SMYD3 siRNAs for 24 h, and then treated with 5 ng/ml TGF for 6 h. mRNA levels
of EMT-TFs was determined by quantitative real-time PCR analysis, relative to GAPDH. Data represent means±SD of nFold relative to a SiScramble
untreated sample. Statistical analysis was performed with unpaired Student’s t test. n≥3, * P ≤ 0.05, ** P ≤ 0.01. (G) Rescue experiment in MCF10A
cells knocked down for SMYD3 by siRNAs and co-transfected with a plasmid carrying the mSMYD3 cDNA. After 24 h, cells were treated with 5 ng/ml
TGF for 72 h. Normalized band intensity in immunoblots is reported above signals. (H) Migration percentage was measured by wound healing assay in
siScramble, siSMYD3 and mSMYD3-reconstituted siSMYD3 MCF10A cells treated with TGF (5 ng/ml) for 16 h. Statistical analysis was calculated
with unpaired Student’s t-test. n ≥3, * P ≤ 0.05. Scale bar = 10 m.
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tion in NMuMG and MCF10A cells and that SMYD3 re-
constitution rescued the defective ability to migrate in both
cell types (Supplementary Figure S2H–J and Figure 1H).
Overall, these data indicate that SMYD3 plays a role in
regulating EMT-TFs and mesenchymal genes transcription
andmodulates TGF-induced cell migration in human and
mouse mammary cells.
SMYD3 pharmacological blockade prevents EMT
SMYD3 function was recently challenged by the small
inhibitor BCI121 (41). Thus, in a parallel set of experi-
ments, SMYD3 was pharmacologically blocked, by treat-
ing both NMuMG and MCF10A cells with increasing
concentration of the SMYD3 inhibitor BCI121. Both cell
lines were initially treated with different doses of BCI121
for 3 h and subsequently co-treated with TGF for addi-
tional 48 h. In NMuMG cells, increasing doses of BCI121
progressively reduced TGF-induced mesenchymal genes
upregulation and epithelial genes downregulation. At the
10 M BCI121 dose, TGF treated NMuMG cells failed
to induce Fibronectin and N-cadherin mesenchymal tran-
scripts and to down-regulate mRNA levels of the epithe-
lial genes E-cadherin and Claudin6. A lower BCI121 dose
(5 M) was sufficient to mask TGF-mediated effects on
Claudin6 and Fibronectin transcript levels (Figure 2A).
Likewise, SMYD3 pharmacological blockade in MCF10A
cells resulted in a modest increase in the mesenchymal tran-
script N-cadherin following TGF treatment, at the 5 M
BCI121 dose, and MMP9 expression was abrogated at the
10 and 50Mdoses (Figure 2B). In agreement with BCI121
ability to temper TGF-induced effects, we also observed
reduced migration ability in BCI121-treated NMuMG and
MCF10A cells (Figure 2C and D).
As previously reported for other cell lines, 72 h BCI121
treatment led to decreased cell viability (41), both in
NMuMG and MCF10A cells. With the exception of the
50 M dose in TGF treated NMuMG cells, BCI121 did
not significantly affect cell growth at 48 h treatment, sug-
gesting that the inhibitor effects on EMT were largely inde-
pendent on its impact on cell proliferation at earlier stages
(Supplementary Figures S3A and S3B). Likewise, SMYD3
genetic depletion did not affect cell growth throughout
TGF treatment, both in NMuMG and MCF10A cells
(Supplementary Figure S3C and D).
Overall, these data suggest that SMYD3 pharmacologi-
cal blockade prevents the full activation of TGF induced
EMT and reduces cell migration.
SMYD3 directly interacts with SMAD3
Transcriptional regulation of TGF modulated genes is
largely controlled by SMAD2/3 transcription factors dur-
ing EMT (39). Therefore, we first checked whether SMYD3
interactedwith SMAD3 inHEK293T cells, transfectedwith
Flag-SMYD3 and HA-SMAD3 plasmids.
Immunoprecipitation experiments revealed that over-
expressed SMYD3 was able to associate to SMAD3, in
the absence of TGF stimulation (Figure 3A). Remark-
ably, exogenously expressed SMAD2 and SMAD4 were
also able to associate with SMYD3 in HEK293T cells
(Supplementary Figure S4A and B). Next, we determined
whether SMYD3 was able to interact with endogenous
SMAD2/3 and performed immunoprecipitation experi-
ments using NMuMG extracts. These experiments indi-
cated that SMDA3/SMYD3 association occurs both in
untreated and TGF-treated cells and that it is not af-
fected by the presence of the TGF inhibitor SB43152 in
growth medium (Figure 3B). Immnuoprecipitation experi-
ments with recombinant GST-SMAD3 and SMYD3 pro-
teins revealed a direct association between the two proteins
in vitro (Figure 3C).
To define the protein domains involved in the interac-
tion, we performed immunoprecipitation experiments in
HEK293T cells over-expressing SMAD3 deletion mutants
with full-length SMYD3 and found that the MH2 do-
main is required for SMYD3 association (Figure 3D and
Supplementary Figure S4C). Co-immunoprecipitation ex-
periments with full-length HA-SMAD3 and Flag-SMYD3
deletionmutants revealed thatmutant SMYD3 encompass-
ing aa 219–428 and aa 111–428 associate with SMAD3 as
the full-length protein. Conversely SMYD3 proteins lack-
ing the C-terminal region (SMYD3 1–219 and SMYD3 1–
380) lost the ability to interact with SMAD3 (Figure 3E and
Supplementary Figure S4D).
To investigate whether SMYD3 C-terminal region is rel-
evant to the modulation of TGF induced genes, we re-
constituted SMYD3-depleted NMuMG cells with the full-
length human SMYD3, hSMYD3 1–380, hSMYD3 111–
428 deletion mutants and the methylation defective
hSMYD3 EEL (Supplementary Figure S4E). Following
TGF treatment, Snail1 and Fibronectin transcript lev-
els were rescued by SMYD3 full-length, hSMYD3 111–
428 and hSMYD3 EEL over-expression, in SMYD3-
depleted cells (Figure 3F). The hSMYD3 1–380mutant, in-
stead, was unable to promote Snail1 and Fibronectin ex-
pression in ShSMYD3 NMuMG cells (Figure 3F).
Furthermore, we tested whether SMYD3 methylase ac-
tivity was functionally indispensable for SMYD3-mediated
EMT regulation. We evaluated the ability of SMYD3 cat-
alytically defective mutant (SMYD3-EEL) to promote
EMT, when compared to wild type SMYD3 (SMYD3-
WT). Both SMYD3-WT and the inactive SMYD3-EEL
mutant promoted upregulation of the mesenchymal genes
N-cadherin and Vimentin, and equally reduced E-cadherin
andOccludin protein levels, as well asmembrane-associated
ZO-1 (Supplementary Figures S4F and S4G). These results
are in agreement with previously reported data (23) and
they suggest that SMYD3-mediated EMT genes regulation
is independent on SMYD3 methylation activity.
Overall, these data suggest that SMYD3 directly interact
with SMAD3 through its C-terminal domain, and this re-
gion is crucial for EMT genes modulation, independently
of SMYD3 methylation activity.
SMYD3 is indispensable for SMAD3 association to the chro-
matin
SMYD3 protein localized both in the cytoplasm and nu-
cleus of TGF-treated NMuMG cells, and was more abun-
dant in the former compartment (Supplementary Figure
S5A). Following TGF treatment, SMAD3primarily local-
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Figure 2. SMYD3 blockade with the BCI121 inhibitor hampers TGF-induced EMT. (A) Epithelial (E-Cadherin, Claudin-6) and mesenchymal (N-
Cadherin and Fibronectin) transcripts were quantified by quantitative real-time PCR analysis, relative to GAPDH. NMuMG cells were treated with 10
ng/ml TGF in the presence of 0, 1, 5 10 and 50 M BCI121, for 48 h. Statistical analysis was performed with one-way ANOVA, followed by post-hoc
Tukey test. Data represent means±SD. n ≥3, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. (B) N-Cadherin and MMP9 transcript levels were quantified by
quantitative real-time PCR normalized to GAPDH in MCF10A cells treated with 5 ng/ml TGF in the presence of 0, 1, 5 10 and 50 M BCI121 for 48
h. Data represent means±SD. Statistical analysis was performed with one-way ANOVA, followed by post-hoc Tukey test. n ≥3, * P ≤ 0.05, ** P ≤ 0.01,
***P ≤ 0.001. (C, D) Wound healing assay on NMuMG and MCF10A cells treated with 10MBCI121 and 5 and 10 ng/ml TGF respectively, for 0 and
16 h. Migration percentage is reported in the right panel. Statistical significance was calculated with paired Student’s t-test. * P ≤ 0.05, *** P ≤ 0.001.
Scale bar = 10 m.
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Figure 3. SMYD3 directly interacts with SMAD3. (A) Western-blot analysis of over-expressed Flag-SMYD3 and HA-SMAD3 following co-
immunoprecipitation with anti-Flag antibody. (B) Co-immunoprecipitation analysis of endogenous SMYD3 and SMAD3 in NMuMG cells. Whole
cell extract were prepared from NMuMG cells after starvation, from cells treated with the TGF-signaling inhibitor SB431542, or starved and treated
with 10 ng/ml TGF for 30 and 60 minutes. IP was performed with antibodies raised against SMYD3. (C) in vitro co-immunoprecipitation of GST-
SMAD3 and SMYD3 was performed with SMYD3 antibodies. Immunoblot was performed with anti-SMAD2/3 and anti-SMYD3 antibodies. (D) Co-
immunoprecipitation with anti-Myc antibody in whole cell extracts of HEK293T cells over-expressingMyc-SMYD3 and Flag-SMAD3WTor Flag-tagged
SMAD3 domains MH1, L-MH2 and MH2. Lower panel represents a schematic representation of SMAD3 mutants. (E) Co-immunoprecipitation with
anti-HA antibody of HEK293T cells over-expressing HA-SMAD3 and Flag-SMYD3 WT or Flag-tagged SMYD3 mutants 1–219, 219–428, 111–428,
1–380. Lower panel represents a schematic representation of SMYD3 mutant. (F) NMuMG cells were transduced with human full-length or SMYD3
mutants by retroviral infection and than knocked down for endogenous SMYD3. 24 h after SMYD3 depletion, cells were treated with 10ng/ml TGF for
12 h (Snail1) or 48 h (Fibronectin). Snail1 and Fibronectin transcripts were quantified by quantitative real-time PCR analysis, relative to GAPDH. nFold is
relative to siScramble untreated cells. SiS refers to SiSMYD3 cells. Statistical analysis was performed with unpaired Student’s t-test. Data represent means
± SD. n = 3, *P ≤ 0.05, **P ≤ 0.01.
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izes in the nucleus, where SMYD3/SMAD3 interaction was
detectable, pointing to a potential role of this interaction in
nuclear functions (Supplementary Figure S5A).
SMYD3 critical role in EMT regulation (23) (Figures 1–
3) prompted us to investigate SMYD3 ability to directly as-
sociate to mesenchymal gene regulatory regions. ChIP as-
says in TGF treated MCF10A cells showed that SMYD3
is recruited at the Snail1, Sox4, MMP9 and Vimentin reg-
ulatory regions. To provide further mechanistic insight, we
assayed SMAD2/3 recruitment at these mesenchymal tar-
get genes in SMYD3 knockdown and control ShScram-
ble cells. Chromatin immunoprecipitation (ChIP) assays re-
vealed that SMAD2/3 engagement at mesenchymal genes
was significantly reduced by SMYD3 depletion (Figure 4A
and Supplementary Figure S5B).
BCI121 is predicted to bind the substrate binding pocket,
and the inner part of the lysine channel, forming hydrogen
bondswith SMYD3Ser202 andTyr239 (41). Thus, by inter-
acting with the histone lysine-binding pocket, BCI121 ex-
erts a dual function on SMYD3, both inhibiting its catalytic
activity and preventing its recruitment to the chromatin
(41). Thus, as a second approach we performed ChIP assays
with BCI121-treatedMCF10A cells, in which BCI121 treat-
ment did not prevent SMAD2/3 interaction with SMYD3
(Supplementary Figure S5C). As expected, BCI121 admin-
istration prevented SMYD3 occupancy at these regulatory
regions. In addition, SMAD2/3 recruitment was also dra-
matically decreased at regulatory regions ofMMP9, Snail1,
Sox4, and Vimentin (Figure 4B and Supplementary Figure
S5D).
Remarkably, both immunoblot and immunofluorescence
experiments revealed that TGF dependent SMAD2/3
phosphorylation was unaffected by SMYD3 knockdown
(Figure 4C and 4D). Likewise, SMAD2/3 nuclear translo-
cation (Figure 4C and E) and SMAD4 interaction (Supple-
mentary Figure S5E) were not influenced by SMYD3 re-
duction, suggesting that SMYD3 depletion did not impair
TGF induced SMAD2/3 nuclear localization.
ChIP assays in NMuMG cells, confirmed a reduction
in SMAD2/3 and SMYD3 occupancy at the Snail1 pro-
moter, in ShSMYD3 TGF-treated cells compared to
ShScramble cells. Additionally, histone marks analysis at
Snail1 regulatory regions revealed that SMYD3 deple-
tion was accompanied by a local decrease in histone
H3K9ac and H3K4me3. Conversely, repressive histone
marks H3K27me3 and H3K9me3 occupancy was compa-
rable in ShSMYD3 and ShScramble cells. Concurrently,
RNA Polymerase II recruitment was reduced at Snail1 pro-
moter in ShSMYD3 NMuMG cells (Figure 4F and Sup-
plementary Figure S5F), in agreement with Snail1 gene re-
duced transcription (Figure 1C).
Taken together, these findings suggest that SMYD3 di-
rectly takes part in the transcriptional regulation of a subset
of mesenchymal genes, and that its engagement correlates
with SMAD2/3 and RNAPolII recruitment at regulatory
regions.
We repeated SMYD3 and SMAD3 ChIP-assays in
SMYD3-depleted NMuMG cells that were reconstituted
with full-length hSMYD3, with the methylation defective
mutant (hSMYD3 EEL) and with the N-term or C-term
deletion mutants (hSMYD3 111–428 and hSMYD3 1–
380). All SMYD3 mutant forms were able to associate to
the Snail1 promoter. ChIP-assays with the SMAD3 an-
tibody revealed that the hSMYD3 1–380 mutant failed
to recruit SMAD3 to the Snail1 promoter (Figure 4G
and Supplementary Figure S5I), in agreement with Snail1
transcript levels reported in Figure 3F. To further dissect
SMYD3/SMAD3 interplay, we evaluated SMYD3 abil-
ity to associate EMT-genes in SMAD3 knocked-down
MCF10A cells, by ChIP assay. SMAD3 was necessary for
SMYD3 recruitment, suggesting that both proteins are re-
quired to promote EMT-genes transcription (Supplemen-
tary Figures S5G and H).
Overall, SMYD3 appears to promote EMT-TFs and
mesenchymal genes transcription by favoring SMAD2/3
chromatin stabilization, in a methylation independent man-
ner.
SMYD3 inhibition decreases MDA-MB-231 mesenchymal
phenotype and cells migration ability
We next asked whether SMYD3 knockdown or pharma-
cological blockade could attenuate the mesenchymal phe-
notype, in a metastatic mesenchymal-like breast cancer cell
line. We therefore treated human MDA-MB-231 cells with
siSMYD3RNAs or BCI121 and assessed whether SMYD3
blockade could reducemesenchymal gene transcription and
promote epithelial markers expression. SMYD3-depleted
cells displayed higher levels of E-cadherin and a reduced ex-
pression of mesenchymal markers (Fibronectin, Vimentin,
Snail1) (Figure 5A). In addition, we treated MDA-MB-231
cells with two doses of BCI121 (10 and 50 M) for 48 h
and found that SMYD3 inhibition increased the expres-
sion of epithelial markers Occludin and Claudin6 and re-
duced the expression of mesenchymal markers Snail2, Fi-
bronectin and N-cadherin (Figure 5B). Snail1, Snail2, Vi-
mentin and Fibronectin protein levels also decreased fol-
lowing BCI121 administration (Figure 5C). Functionally,
BCI121 treatment decreased MDA-MB-231 ability to mi-
grate in vitro, as shown by wound-healing assays (Figure
5D).
MDA-MB-231 cells have been employed to evaluate in
vivomigration, in zebrafish xenografts. MDA-MB-231 cells
were injected in the sub-peridermal space, close to the sub-
intestinal vessels (SIV) plexus, in zebrafish embryos at 48 h
post fertilization (hpf). After cells injection, embryos were
treated either with 50 M BCI121 or DMSO for 48 h. We
then evaluated the number of single cells that invaded the
zebrafish body, either in the tail, heart or head, at 2 days
post-injection (dpi). We found that the number of invading
MDA-MB-231 cells was significantly reduced in zebrafish
embryos treated with BCI121, when compared to DMSO
treated embryos (Figure 5E and F).
Overall, these results indicate that BCI121 treatment de-
creases MDA-MB-231 cells mesenchymal signature and it
reduces their invasion ability, both in vitro and in vivo.
SMYD3 is highly expressed in human breast cancers and cor-
relates with increased metastasis
To assess whether our findings could be related to the patho-
genesis of human breast cancer and metastasis formation,
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Figure 4. SMYD3 assists SMAD3 recruitment to the chromatin. (A) SMAD2/3 and SMYD3 association to regulatory regions of EMT markers was
analyzed by ChIP qPCR, in ShScramble and ShSMYD3 MCF10A cells treated with 5ng/ml TGF for 24 h. Data are expressed as fold enrichment
relative to ShScramble cells and represent means±SD. Statistical analysis was performed with Student’s t test. n = 4, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤
0.001. (B) SMAD2/3 and SMYD3 association to EMT markers was analyzed by ChIP qPCR, in MCF10A cells co-treated with 5ng/ml TGF and 10
M BCI121 for 24 h. Data are expressed as fold enrichment relative to control cells. Data represent means±SD. Statistical analysis was performed with
unpaired Student’s t test. n = 4, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. (C) immunofluorescence microscopy of shSMYD3 or shScramble NMuMG cells
treated with 10 ng/ml TGF for 2 h. The staining for the phosphorylated SMAD3 (P-SMAD3) (left panel), for DAPI (center panel) and the merge of
the two stainings (right panel) are shown. Scale bar = 10 m. (D) Western-blot analysis of P-SMAD3 and SMAD2/3 levels in shSMYD3 or shScramble
NMuMG cells, treated with 10 ng/ml TGF for for 30 min. Relative band intensity, normalized over total SMAD2/3 proteins, is indicated. (E) Western-
blot analysis of cytoplasmic (C) and nuclear (N) P-SMAD3 in shSMYD3 or shScramble NMuMG cells treated with 10 ng/ml TGF for 30 min. GAPDH
was used as cytoplasmic marker, histone H3 as nuclear marker. (F) ChIP assay was performed to evaluate SMYD3, SMAD2/3, RNAPolII, H3K9me3,
H3K9Ac, H3K27me3 occupancy at the Snail1 promoter, in NMuMG cells treated with 10ng/ml TGF for 6 h. Data are normalized on IgG and represent
means ± SD. Statistical analysis was performed with Student’s t test. n = 3, * P ≤ 0.05, ** P ≤ 0.01. (G) ChIP assay was performed to evaluate SMYD3
and SMAD2/3 occupancy at the Snail1 promoter, in NMuMG cells obtained as in Figure 3F, treated with 10ng/ml TGF for 6 h. SiS refers to SiSMYD3
cells. Data are normalized on IgG and represent means±SD. Statistical analysis was performed with unpaired Student’s t test. n = 3, * P ≤ 0.05, ** P ≤
0.01, *** P ≤ 0.001.
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Figure 5. SMYD3 knock down or pharmacological blockade tempers MDA-MB-231 mesenchymal phenotype and migration ability. (A) SMYD3 was
knocked down by siRNA transfection in MDA-MB-231 cells, total extracts were collected after 48 h and assayed for epithelial (E-cad) or mesenchymal
(Fibronectin, Vimentin and Snail1) protein levels by immunoblot.GAPDHwas used as a loading control. nFold is relative toDMSO treated cells. (B)MDA-
MB-231 cells were treated with increasing doses of BCI121 (0, 10 or 50 M) for 48 h. Epithelial (Occludin, Claudin6) or mesenchymal (Snail2, N-cadherin
and Fibronectin) marker mRNA levels were measured by qRT-PCR. GAPDH was used as housekeeping gene. Data represent means±SD. Statistical
analysis was performed with 1 way ANOVA, followed by post-hoc Tukey test n ≥3, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. (C) MDA-MB-231 cells were
treated with increasing doses of BCI121 (0, 10 or 50 M) for 72 h and whole cell extracts were assayed for mesenchymal (Snail1, Snail2, Vimentin and
Fibronectin) protein levels by immunoblot. GAPDH was used as a loading control. (D) Wound-healing assay on MDA-MB-231 cells treated with 10 M
BCI121 for 0 and 16 h. Migration percentage is reported in the right panel. Statistical significance was calculated with Student’s t-test. *** P≤ 0.001. Scale
bar= 10m. (E) in vivomigration assay in zebrafish xenografts. 1× 102 MDA-MB-231 cells were injected in the subepidermal pocket of zebrafish embryos
at 48 hpf. Embryos were treated with 50 MBCI-121 or DMSO, for 48 h, n = 14 DMSO embryos, n = 12 BCI121 embryos. (F) Cells migrating in the tail,
heart and head were counted in the two groups, 48 hpi. Scale bar = 200m. Statistical analysis was performed with unpaired Student’s t-test. * P ≤ 0.05.
Normalized band intensity in immunoblots is reported above signals.
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we studied SMYD3 expression in one of the publicly avail-
able data sets in the TCGA repository (Supplementary Fig-
ure S1). In theMetabric cohort (35, 36) SMYD3was altered
in 24.1% of the 2501 cases (Supplementary Figure S1).
Analysis of RNA-seq expression profiles of breast inva-
sive carcinomas obtained from the TCGA database and an-
alyzed with the Firebrowse portal showed that SMYD3 ex-
pression was significantly enhanced in breast cancer tumors
(1093 tumor samples) when compared to healthy tissue (112
normal samples) (Figure 6A). Remarkably, we could not
point out any specific SMYD3 enrichment in relation to
any breast cancer molecular subtype or in relation to dif-
ferent tumor stages (Supplementary Figure S6A and B).
We next focused on EMT signature genes and interrogated
expression data from 1394 tumor samples obtained from
the Metabric dataset to investigate whether SMYD3 tran-
script levels were associated with EMT genes expression.
We stratified patients for SMYD3 levels (Supplementary
Figure S6C), and found that Snail2, Zeb1, Zeb2, Twist1,
Twist2, N-cadherin, Fibronectin and Vimentin were sig-
nificantly upregulated in high SMYD3 tumors compared
to the low SMYD3 group (Supplementary Figure S6D).
We observed a positive correlation between SMYD3 and
mesenchymal genes expression (Snail2, Zeb1, Zeb2, Fi-
bronectin, N-Cadherin and Twist1) in the Metabric dataset
(Supplementary Figure S6E). To confirm our findings, we
extended our analysis to the NKI295 breast cancer dataset
(42), and confirmed a positive correlation between SMYD3
and Snail2, N-cadherin and Fibronectin expression (Sup-
plementary Figure S6F).
Core-EMT signature genes are highly expressed in
claudin-low breast cancers, when compared to other molec-
ular breast cancers subtypes (20). We therefore queried
for a correlation between SMYD3 expression and a sub-
set of core-EMT genes in claudin-low tumors, within the
Metabric dataset. Our analysis confirmed a positive corre-
lation between SMYD3 expression and EMT-TFs (Snail2,
Zeb2, Zeb1, Twist1), as well as mesenchymal gene tran-
scripts (Fibronectin, N-Cadherin) and the degree of cor-
relation was more robust in claudin-low subtype than in
the whole Metabric cohort (Figure 6B and Supplementary
Figure S6E). The basal subtype of breast cancers differ
from claudin-low tumors for a lower expression of EMT-
signature transcripts and TGF activation pathway (20).
Remarkably, the correlation betweenmesenchymal markers
and SMYD3 transcript levels was less evident in the basal
tumors subgroup than in claudin-low tumors (Figure S7A).
Transcript levels for Snail2, ZEB1, ZEB2, Twist1, Vi-
mentin andFibronectinwere significantly higher in claudin-
low tumors over-expressing SMYD3 compared to the
SMYD3 low tumors (Figure 6C), and the differences be-
tween the two groupsweremore prominent than in the anal-
ysis on the entire dataset and the basal subtype (Figure 6C,
Supplementary Figures S6D and S7B).
SMYD3 higher expression levels did not correlate with a
poorer prognosis in theMetabric cohort as a whole or in the
basal subtype subgroup of patients (Supplementary Figure
S7C and D); however, SMYD3 high patients had a signifi-
cantly lower survival probability in the claudin-low tumor
subgroup, when compared to the claudin-low SMYD3 low
patients’ group (Figure 6D).
To further investigate SMYD3 prognostic value, we per-
formed a parallel analysis in different clinical microarray
datasets from 1354 breast tumors (43). We first focused our
analysis to an advanced tumor stage, and found that dis-
tant metastasis free survival was significantly higher for pa-
tients with low SMYD3 grade 3 tumors, independently of
lymph node status and systemic treatment they underwent
(n = 458, P value 0.022) (Figure 6E). Likewise, SMYD3
high levels in grade 1 lymph node negative tumors, in pa-
tients that didn’t undergo chemotherapy or endocrine ther-
apy, displayed a significantly lower probability of distant
metastasis free survival (n= 94, P= 0.031) (Supplementary
Figure S7E).
Overall, clinical dataset analysis indicates that SMYD3
levels positively correlate with EMT-TFs and mesenchy-
mal gene expression in breast tumors. Higher SMYD3 lev-
els in breast tumors associate with reduced metastasis free
survival, and with a worst overall survival probability in
claudin-low tumors.
DISCUSSION
Results presented in this paper highlight SMYD3 nu-
clear functions in regulating EMT-TFs and mesenchymal
gene expression, in the context of TGF stimulation. We
describe a direct TGF-independent interaction between
SMYD3 and SMAD3, and a functional interplay between
SMYD3 and SMAD3 inEMTgenes transcriptional regula-
tion. We propose that SMYD3 is indispensable for TGF-
induced SMAD3 recruitment at chromatin regulatory re-
gions of mesenchymal targets and EMT-TFs. Remark-
ably, SMAD3 is likewise necessary for SMYD3 associa-
tion, suggesting that both factors are required for transcrip-
tional competence and that SMYD3may stabilize SMAD3-
orchestrated complex and potentiate transcriptional activa-
tion.
Several lines of evidence previously linked SMYD3 tomi-
gration and invasion, in different cell lines 22,24. Our find-
ings confirm this indication in TGF-induced EMT and
provide a molecular mechanism that supports recently re-
ported in vivo findings (23), highlighting a crucial role for
SMYD3 in promoting EMT genes activation. Sarris et al.
(23) showed by ChIP-Seq assay that SMYD3 occupies sev-
eral regulatory regions in liver tumors and revealed that
SMYD3 association to a subset of proliferation and EMT
loci promotes their transcriptional activation. We propose
that SMYD3 cooperates with SMAD3 at EMT genes, driv-
ing mesenchymal and EMT-TFs transcription. Following
TGF-mediated stimulation, SMAD2 and SMAD3 are ac-
tivated, translocate to the nucleus and bind to different tran-
scription factors, co-activators or co-repressors thus achiev-
ing higher affinity and selectivity for target genes regulatory
regions (16). In different cell types SMAD3 occupancy is
directed by cell-type-specific master transcription factors,
which are responsible for orchestrating the cell-type-specific
effects of TGF signaling (44). Therefore, cell-type-specific
effects of TGF signaling are in large part determined by
SMAD2/3 interactions with transcription factors and co-
factors and they can vary in a cell/tissue-specific manner.
In this scenario, we propose that SMYD3 takes part in
the orchestrated SMAD3 recruitment at a subset of mes-
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Figure 6. Prognostic value of SMYD3 in breast cancer. (A) Box plots showing SMYD3 expression levels in normal and tumor breast tissues. Analysis was
performed on 1098 breast cancer tissues and 112 normal tissues on TCGAdata, downloaded through Firebrowse. ***P< 0.0001, unpaired Student’s t test.
(B) Correlation between SMYD3 and the mesenchymal markers Snail2, ZEB1, ZEB2, TWIST1, Fibronectin and N-Cadherin expression, calculated on
claudin-low tumors (Metabric), by Pearson correlation analysis. Pearsons’ coefficient tests were performed to assess statistical significance. (C) Claudin-low
tumors (Metabric) were stratified for SMYD3 expression (high vs low) and Snail2, ZEB1, ZEB2, TWIST1, TWIST2, Vimentin, Fibronectin mRNA levels
were compared in SMYD3 low and SMYD3 high tumors. Statistical significance was calculated with unpaired Student’s t test. *P ≤ 0.05, **P ≤ 0.001,
***P ≤ 0.0001. (D) Kaplan–Meier plots of survival probability of claudin-low patients stratified by SMYD3 expression in the Metabric dataset. P value
calculated by log rank test. (E) Kaplan–Meier plots of distant metastasis-free survival of patients with grade 3 tumors, stratified by SMYD3 expression
levels. P value was calculated by log rank test.
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enchymal and EMT-TFs genes, following TGF stimula-
tion. SMAD3 interacts with SMYD3 through theMH2 do-
main, which is responsible for association to various tran-
scription factors and cofactors, for the interaction between
SMAD proteins and that is also crucial for transcriptional
activation (45). SMYD3 interaction domain, instead, en-
compasses the SMYD3C-terminal region, whichwas previ-
ously reported to be involved in HSP90 (46) and H3K4me3
interaction in vitro (23).
Our ChIP data show that SMYD3 depletion does
not affect distribution of the repressive histone marks
H3K9me3 and H3K27me3 at the Snail1 promoter. These
findings are in agreement with the concept that SMYD3
is recruited at open-chromatin regions (23) and suggest
that SMYD3/SMAD2/3 independent mechanisms are in-
volved in H3K9me3 and H3K27me3 removal (47). Con-
versely, SMYD3 promotes H3K4me3 and H3K9Ac marks
deposition at the Snai1 promoter, as well as SMAD3
and RNAPolII recruitment, and transcriptional activation.
These data suggest that SMYD3 association to the Snail1
gene is subsequent to repressive histone marks removal and
that SMYD3 association promotes transcription through
SMAD2/3 complex stabilization and RNAPolII recruit-
ment, at EMT loci. SMAD3was previously reported to me-
diate COMPASS recruitment and precede H3K4 trimethy-
lation at the Snail1 promoter, in TGF-treated DU145 cells
(48). Additionally, SMAD3 interacts with p300/CBP and
TGF treatment promotes acetylation of SMAD2/3 tar-
get genes (49,50), further suggesting that SMAD2/3 asso-
ciation to the chromatin is required to promote H3K4me3
and H3K9Ac. Additionally, SMYD3 associates with the
RNAPolII complex (30,51), and this interaction may favor
the transcriptional machinery recruitment at EMT genes.
Remarkably, SMYD3-mediated regulation of EMT is in-
dependent of its catalytic activity, suggesting that SMYD3
co-activator functions are not mediated by SMYD3 methy-
lation activity at the mesenchymal/EMT-TFs genes. Like-
wise, SMYD3 knockdown did not lead to ERK and
AKT phosphorylation modulation (25,40,41), indicating
that SMYD3 cytosolic and methylation-dependent mech-
anisms are finely tuned and operate differently in different
context.
In the patho-physiological context, patients’ data on sur-
vival and metastasis free survival support the experimen-
tally described SMYD3 role in promoting EMT. SMYD3
mRNA levels are upregulated in breast cancers compared
to normal breast tissues, but SMYD3 transcripts appear to
be upregulated in all breast cancer subtypes. SMYD3 also
promotes transcriptional activation of proliferation genes
and its augmented levels may confer an advantage for tu-
mor growth in different breast cancer subtypes. Addition-
ally, SMYD3 was shown to regulate HER2 dimerization
through direct methylation (52), suggesting that in differ-
ent breast cancer subtypes SMYD3 may provide selective
growth advantages, through distinct mechanisms.
Remarkably, we were unable to observe a significant cor-
relation between Snail1 and SMYD3 expression in our
bioinformatics analysis of breast tumor datasets. Although
Snail1 transcriptional upregulation is known to occur fol-
lowing TGF stimulation, experimental models of breast
cancer have shown that Snail1 transient expression in the
primary tumor is sufficient to increase lung metastasis (53)
and that TGF signaling is a transient and spatially re-
stricted event, suggesting that Snail1 plays a crucial role in
EMT initiation, while other EMT-TFs participate in EMT
maintenance (53,54).
Claudin-low breast cancer cells were shown to be more
likely than other breast cancer subtypes to promote the
breast tumor initiating cancer cell (BTICs) population
in response to TGF (55). We propose that in TGF
sensitive cells, such as claudin-low cancer cells, SMYD3
may promote EMT genes activation through its interplay
with SMAD3. Recent evidences show that EMT-associated
markers are highly expressed in cancer stem cells and pro-
mote their self-renewal (4). Remarkably, BTICs are en-
riched within the claudin-low molecular subtype of breast
cancer, where TGF/SMAD signaling promote BTICs ex-
pansion (55). Further investigations will reveal whether
SMYD3 likewise promotes BTICs stemness in claudin-low
cells.
Overall, our data further support SMYD3 as a promising
pharmacological target for anti-cancer therapy.
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